An Vandebosch
Overview
Explore the profile of An Vandebosch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
1872
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Carpp L, Hyrien O, Fong Y, Benkeser D, Roels S, Stieh D, et al.
Nat Commun
. 2024 Nov;
15(1):9785.
PMID: 39532861
Assessment of immune correlates of severe COVID-19 has been hampered by the low numbers of severe cases in COVID-19 vaccine efficacy (VE) trials. We assess neutralizing and binding antibody levels...
2.
Magaret C, Li L, deCamp A, Rolland M, Juraska M, Williamson B, et al.
Nat Commun
. 2024 Mar;
15(1):2175.
PMID: 38467646
In the ENSEMBLE randomized, placebo-controlled phase 3 trial (NCT04505722), estimated single-dose Ad26.COV2.S vaccine efficacy (VE) was 56% against moderate to severe-critical COVID-19. SARS-CoV-2 Spike sequences were determined from 484 vaccine...
3.
Magaret C, Li L, deCamp A, Rolland M, Juraska M, Williamson B, et al.
Res Sq
. 2023 Jul;
PMID: 37398105
It is of interest to pinpoint SARS-CoV-2 sequence features defining vaccine resistance. In the ENSEMBLE randomized, placebo-controlled phase 3 trial, estimated single-dose Ad26.COV2.S vaccine efficacy (VE) was 56% against moderate...
4.
Turley C, Tables L, Fuller T, Sanders L, Scott H, Moodley A, et al.
Vaccine
. 2023 Jun;
41(33):4899-4906.
PMID: 37385888
Questions remain regarding the effect of baseline host and exposure factors on vaccine efficacy (VE) across pathogens and vaccine platforms. We report placebo-controlled data from four Phase 3 COVID-19 trials...
5.
Fong Y, McDermott A, Benkeser D, Roels S, Stieh D, Vandebosch A, et al.
Nat Microbiol
. 2022 Nov;
7(12):1996-2010.
PMID: 36357712
Measuring immune correlates of disease acquisition and protection in the context of a clinical trial is a prerequisite for improved vaccine design. We analysed binding and neutralizing antibody measurements 4...
6.
Hardt K, Vandebosch A, Sadoff J, Le Gars M, Truyers C, Lowson D, et al.
Lancet Infect Dis
. 2022 Sep;
22(12):1703-1715.
PMID: 36113538
Background: Despite the availability of effective vaccines against COVID-19, booster vaccinations are needed to maintain vaccine-induced protection against variant strains and breakthrough infections. This study aimed to investigate the efficacy,...
7.
Fong Y, McDermott A, Benkeser D, Roels S, Stieh D, Vandebosch A, et al.
medRxiv
. 2022 Apr;
PMID: 35441174
Anti-spike IgG binding antibody, anti-receptor binding domain IgG antibody, and pseudovirus neutralizing antibody measurements four weeks post-vaccination were assessed as correlates of risk of moderate to severe-critical COVID-19 outcomes through...
8.
Sadoff J, Gray G, Vandebosch A, Cardenas V, Shukarev G, Grinsztejn B, et al.
N Engl J Med
. 2022 Feb;
386(9):847-860.
PMID: 35139271
Background: The Ad26.COV2.S vaccine was highly effective against severe-critical coronavirus disease 2019 (Covid-19), hospitalization, and death in the primary phase 3 efficacy analysis. Methods: We conducted the final analysis in...
9.
Van Lancker K, Vandebosch A, Vansteelandt S
Biom J
. 2021 Jul;
63(7):1464-1475.
PMID: 34247409
Motivated by a clinical trial conducted by Janssen Pharmaceutica in which a flexible dosing regimen is compared to placebo, we evaluate how switchers in the treatment arm (i.e., patients who...
10.
Vandebosch A, Sadoff J, Douoguih M
N Engl J Med
. 2021 Jun;
385(3):288.
PMID: 34107179
No abstract available.